{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:37:18Z","timestamp":1751279838112,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fund of the Mayor of Vienna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2876-0","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:54:50Z","timestamp":1537059290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves\u2019 ophthalmopathy \u2013 a 1-year follow-up: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Lindsay","family":"Brammen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-6606","authenticated-orcid":false,"given":"Philipp","family":"Riss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alois","family":"Gessl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Dunkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuren","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Leisser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Rezar-Dreindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Eibenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Selberherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Scheuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"key":"2876_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.autrev.2014.01.013","volume":"13","author":"F Menconi","year":"2014","unstructured":"Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves' disease. Autoimmun Rev. 2014;13:398\u2013402.","journal-title":"Autoimmun Rev"},{"key":"2876_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","volume":"2","author":"GS Cooper","year":"2003","unstructured":"Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2:119\u201325.","journal-title":"Autoimmun Rev"},{"key":"2876_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00268-008-9497-9","volume":"32","author":"P Stalberg","year":"2008","unstructured":"Stalberg P, Svensson A, Hessman O, Akerstrom G, et al. Surgical treatment of Graves' disease: evidence-based approach. World J Surg. 2008;32:1269\u201377.","journal-title":"World J Surg"},{"key":"2876_CR4","first-page":"747","volume":"14","author":"HB Burch","year":"1993","unstructured":"Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747\u201393.","journal-title":"Endocr Rev"},{"key":"2876_CR5","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","volume":"329","author":"RS Bahn","year":"1993","unstructured":"Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med. 1993;329:1468\u201375.","journal-title":"N Engl J Med"},{"key":"2876_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, Eckstein A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273\u201385.","journal-title":"Eur J Endocrinol"},{"key":"2876_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol. 1997;47:9\u201314.","journal-title":"Clin Endocrinol"},{"key":"2876_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1210\/jcem-44-1-203","volume":"44","author":"SC Werner","year":"1977","unstructured":"Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44:203\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"2876_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.beem.2011.09.005","volume":"26","author":"L Hegedus","year":"2012","unstructured":"Hegedus L, Bonnema SJ, Smith TJ, Brix TH. Treating the thyroid in the presence of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:313\u201324.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2876_CR10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00268-008-9910-4","volume":"33","author":"YA Elsayed","year":"2009","unstructured":"Elsayed YA, Abdul-Latif AM, Abu-Alhuda MF, Halim HA. Effect of near-total thyroidectomy on thyroid orbitopathy due to toxic goiter. World J Surg. 2009;33:758\u201366.","journal-title":"World J Surg"},{"key":"2876_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000356042","volume":"2","author":"L Bartalena","year":"2013","unstructured":"Bartalena L. Graves' orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2:259\u201369.","journal-title":"Eur Thyroid J."},{"key":"2876_CR12","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168\u201399.","journal-title":"Endocr Rev"},{"key":"2876_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1210\/jc.2006-1800","volume":"92","author":"F Menconi","year":"2007","unstructured":"Menconi F, Marino M, Pinchera A, Rocchi R, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab. 2007;92:1653\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"2876_CR14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1210\/jc.2013-3093","volume":"99","author":"M Moleti","year":"2014","unstructured":"Moleti M, Violi MA, Montanini D, Trombetta C, et al. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe Graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab. 2014;99:1783\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2876_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1530\/acta.0.1200689","volume":"120","author":"H Schleusener","year":"1989","unstructured":"Schleusener H, Schwander J, Fischer C, Holle R, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol. 1989;120:689\u2013701.","journal-title":"Acta Endocrinol"},{"key":"2876_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/BF03349833","volume":"18","author":"P Vitti","year":"1995","unstructured":"Vitti P, Rago T, Mazzeo S, Brogioni S, et al. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Investig. 1995;18:857\u201361.","journal-title":"J Endocrinol Investig"},{"key":"2876_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"Vitti P, Rago T, Chiovato L, Pallini S, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369\u201375.","journal-title":"Thyroid"},{"key":"2876_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ecl.2009.01.009","volume":"38","author":"L Hegedus","year":"2009","unstructured":"Hegedus L. Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin N Am. 2009;38:355\u201371. ix","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2876_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5603\/NMR.2011.0006","volume":"14","author":"E Gurgul","year":"2011","unstructured":"Gurgul E, Sowinski J. Primary hyperthyroidism\u2014diagnosis and treatment. Indications and contraindications for radioiodine therapy. Nucl Med Rev Cent East Eur. 2011;14:29\u201332.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"2876_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1210\/jcem-27-4-582","volume":"27","author":"JP Kriss","year":"1967","unstructured":"Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, et al. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinol Metab. 1967;27:582\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"2876_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"L Tallstedt","year":"1992","unstructured":"Tallstedt L, Lundell G, Torring O, Wallin G, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733\u20138.","journal-title":"N Engl J Med"},{"key":"2876_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Manetti L, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73\u20138.","journal-title":"N Engl J Med"},{"key":"2876_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","volume":"69","author":"SH Acharya","year":"2008","unstructured":"Acharya SH, Avenell A, Philip S, Burr J, et al. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008;69:943\u201350.","journal-title":"Clin Endocrinol"},{"key":"2876_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 2008;18:333\u201346.","journal-title":"Thyroid"},{"key":"2876_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1089\/thy.2010.1640","volume":"20","author":"KA Ponto","year":"2010","unstructured":"Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid. 2010;20:785\u201393.","journal-title":"Thyroid"},{"key":"2876_CR26","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s40618-016-0484-y","volume":"39","author":"HX Li","year":"2016","unstructured":"Li HX, Xiang N, Hu WK, Jiao XL. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Investig. 2016;39:1225\u201333.","journal-title":"J Endocrinol Investig"},{"key":"2876_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.surg.2016.06.066","volume":"161","author":"VT Wu","year":"2017","unstructured":"Wu VT, Lorenzen AW, Beck AC, Reid VJ, et al. Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves\u2019 disease. Surgery. 2017;161:147\u201355.","journal-title":"Surgery"},{"key":"2876_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/thy.1992.2.171","volume":"2","author":"C Marcocci","year":"1992","unstructured":"Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, et al. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid. 1992;2:171\u20138.","journal-title":"Thyroid"},{"key":"2876_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1089\/thy.2005.15.569","volume":"15","author":"G Lal","year":"2005","unstructured":"Lal G, Ituarte P, Kebebew E, Siperstein A, et al. Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid. 2005;15:569\u201374.","journal-title":"Thyroid"},{"key":"2876_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000339473","volume":"1","author":"S Kautbally","year":"2012","unstructured":"Kautbally S, Alexopoulou O, Daumerie C, Jamar F, et al. Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves' disease previously treated with antithyroid drugs. Eur Thyroid J. 2012;1:122\u20138.","journal-title":"Eur Thyroid J"},{"key":"2876_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s002680010216","volume":"24","author":"J Witte","year":"2000","unstructured":"Witte J, Goretzki PE, Dotzenrath C, Simon D, et al. Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg. 2000;24:1303\u201311.","journal-title":"World J Surg"},{"key":"2876_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12020-011-9559-x","volume":"41","author":"A De Bellis","year":"2012","unstructured":"De Bellis A, Conzo G, Cennamo G, Pane E, et al. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine. 2012;41:320\u20136.","journal-title":"Endocrine"},{"key":"2876_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/thy.1999.9.259","volume":"9","author":"QY Duh","year":"1999","unstructured":"Duh QY. Thyroidectomy for the treatment of Graves' disease. Thyroid. 1999;9:259\u201361.","journal-title":"Thyroid"},{"key":"2876_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320\u201332.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2876-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2876-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2876-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T19:11:14Z","timestamp":1568488274000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2876-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2876"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2876-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,9,15]]},"assertion":[{"value":"5 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"the start of the trial the independent Ethics Committee of the Medical University Vienna gave a positive vote on the protocol and consent to participate. (Protocol record 1839\/2015). The trial was registered at the European Clinical Trials Database (Eudra-CT: 2015\u2013003515-38).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"In consenting to participate in the clinical trial, all patients also consent to publication, as is stated in their consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"495"}}